Metabolomics market – Global opportunity & forecast 2023-2030
The systematic identification and measurement of all metabolites in a specific organism or biological sample are known as metabolomics. Studies on the small molecule biochemistry of bacteria, plants, and mammals have increased as a result of the development of nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and powerful chemometric software that allows the simultaneous determination and comparison of thousands of chemical entities. The two main categories of metabolomics services are targeted and untargeted.
The market worth of metabolomics in 2021 was USD 2.15 billion and will reach USD 6.68 billion by 2030 at a 13.4% CAGR during 2021-2030.
Technological developments in the field of metabolic illness testing, an increase in the production of personalized and generic drugs using metabolomics, and an increase in the prevalence of chronic diseases, including cancer and cardiovascular disease, are the main drivers of the industry. The high starting costs of equipment and the requirement for highly skilled workers to operate such devices have a significant impact on the development of the metabolomics sector.
The rise in private and government sector financing for technical research, as well as the growth of key players’ alliances and partnerships for the improvement of their product portfolio, are only a few of the reasons influencing the growth of the metabolomics sector. The leading companies have significantly increased their R&D spending in order to create cutting-edge metabolomics platforms, which is anticipated to propel the market’s expansion throughout the course of the projected year. The development of personalized medicine also contributes to the market’s expansion.
Massive volumes of diverse data that are difficult to analyze are produced by metabolomics procedures. Due to the chemical diversity of the small molecule metabolites, it is quite challenging to assess the data using just one analytical approach. These elements may slow the market’s overall growth rate in the years to come.
Key firms have a tremendous opportunity to explore the unexplored market in developing nations thanks to the metabolomics sector. The wide range of upcoming research in the area of developing biomarkers also offers enormous prospects for the expansion of the global metabolomics market.
On the basis of products and services, the metabolomics instruments segment led the overall market with the highest market share of 60% in 2020. It is due to metabolomics’ quick uptake and the smooth technical operations that further promote workflow efficiency, accuracy, reliability, and data processing.
On the basis of application, Due to the growing adoption of metabolic biomarkers and technical improvements, the biomarker discovery sector led the market in 2020 with a consistent CAGR. Additionally, among all chronic diseases, the rise in cancer cases worldwide is a key factor in the development of new drugs and biomarkers. The demand for new medication discovery is increasing quickly as a result of the increasing number of cases and the increasing number of persons undergoing urgent oncology tests.
On the basis of indication, the cancer segment ruled the overall market. According to GLOBOCAN 2020, there will be an estimated 19,292,789 new cancer cases and roughly 9,958,133 fatalities in 185 nations by 2020. This is a result of an increase in cancer diagnoses and a growth in the demand for cancer treatment therapies.
On the basis of end-user, in 2020, academic and research institutions ruled the entire market. It is because metabolomics research is becoming more active and funding for the study has been added to educational and research institutions.
North America significantly ruled the overall market with the highest market share in 2020. It is due to the existence of key market players working in the sector, expanding research and development, and increasing preclinical efforts by pharma companies. As per reports from the Centers for Disease Control and Prevention, 6 in 10 individuals in the United States have a chronic disease as of January 2022, while 4 out of 10 adults have more than one or two. The high rate of chronic diseases necessitates the advancement of novel, cutting-edge therapies, increasing the use of metabolomics and fostering business expansion.
- GE Healthcare
- Hitachi High-Technologies Corporation
- Waters Corporation
- Merck KGaA
- Human Metabolome Technologies, Inc.
- Bio-Rad Laboratories
- Agilent Technologies
- LECO Corporation (US),
- Metabolon, Inc.
- Shimadzu Corporation
- Bruker Corporation
- Thermo Fisher Scientific
- GL Sciences
- SRI Instruments
- Danaher Corporation
- Scion Instruments
- DANI Instruments S.p.A.
- Kore Technology Ltd.
- JASCO, Inc.
The market worth of metabolomics in 2021 was USD 2.15 billion and will reach USD 6.68 billion by 2030 at a 13.4% CAGR during 2021-2030. Precision medicine’s increasing significance for the early detection of long-term diseases is one of the major factors driving the metabolomics market. The metabolomics market will advance in the following years due to the spike in technological developments in metabolomics analysis methods and R&D spending.